Hostname: page-component-89b8bd64d-ksp62 Total loading time: 0 Render date: 2026-05-10T02:06:35.691Z Has data issue: false hasContentIssue false
  • English
  • Français

Introduction

Published online by Cambridge University Press:  07 November 2014

Jeffrey L. Cummings
Jeffrey L. Cummings*
Affiliation:
Dr. Cummings is Augustus S. Rose Professor of Neurology, professor of psychiatry and biobehavioral science, director of the Mary S. Easton Center for Alzheimer’s Disease Research, and director of the Deane F. Johnson Center for Neurotherapeutics at the David Geffen School of Medicine at the, University of California, Los Angeles
Get access Rights & Permissions [Opens in a new window]

Extract

Alzheimer’s disease (AD) research is progressing rapidly and on multiple fronts. Advances are being made in early diagnosis, neuroimaging, and biomarkers; optimal care uses currently available medications and strategies; and new therapies are emerging. Early diagnosis is necessary for optimal patient management. Biomarkers are critical to early diagnosis, and biomarker development is dependent on better understanding of disease pathophysiology (Slide 1). The discussions in this supplement examine how progress in AD research can be translated into clinical care.

Primary care practitioners (PCPs) provide most of the care of patients with AD, and these clinicians are optimally poised to discover new cases emerging among elderly patients. Caregivers are most likely to voice concerns about declining memory in a family member to a PCP before seeking specialty evaluation. PCPs, however, have little time to devote to complex assessments and cannot have specialty-level expertise in all disorders. PCPs must have clinical tools that assist them in rapidly identifying potential problems and triaging them for further evaluation or specialty referral.

Information

Type
Research Article
Information
CNS Spectrums , Volume 13 , Issue S16 , 2008 , pp. 4 - 5
Copyright
Copyright © Cambridge University Press 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1.Borson, S, Scanlan, JM, Watanabe, J, Tu, SP, Lessig, M. Improving identification of cognitive impairment in primary care. Int J Geriatr Psychiatry. 2006;21:349–355.CrossRefGoogle ScholarPubMed
2.Nasreddine, ZS, Phillips, NA, Bedirian, V, et al.The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695–699.CrossRefGoogle Scholar
3.Harrison, J, Minassian, SL, Jenkins, L, Black, RS, Koller, M, Grundman, M. A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch Neurol. 2007;64:1323–1329.CrossRefGoogle ScholarPubMed
4.Nestor, SM, Rupsingh, R, Borrie, M, et al.Ventricular enlargement as a possible measure of Alzheimer’s disease progression validated using the Alzheimer’s disease neuroimaging initiative database. Brain. Epub ahead of print.Google Scholar
5.Silverman, DHS, Truong, CT, Kin, SK, et al.Prognostic value of regional cerebral metabolism in patients undergoing dementia evaluation: comparison of quantifying parameter of subsequent cognitive performance and to prognostic assessment without PET. Molec Gen Metab. 2003;80:350–355.CrossRefGoogle ScholarPubMed
6.Klunk, WE, Engler, H, Nordberg, A, et al.Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306–319.CrossRefGoogle ScholarPubMed